Altered Presence of Cancer Stem Cell ALDH1/2 in Oral Leukoplakias and Squamous Cell Carcinomas.
aldh
cancer stem cells
oral cancers
oral leukoplakia
oscc
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
22
06
2023
medline:
25
7
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
epublish
Résumé
Cancer stem cells (CSCs) are responsible for initiating the process of carcinogenesis by enabling the self-renewal and self-proliferation of the cancer cells. This study aimed to investigate the presence of epithelial cells with cancer stem cells characteristics (ALDH+) in the early stages of oral precancerous lesions (Oral Leukoplakias) and the frequency of these cells in the different stages of oral squamous cell carcinomas (OSCCs). The aim of this study was the detection of the immunohistochemical pattern of expression of CSC protein-biomarker ALDH1&2 (sc-166362, Santa Cruz Co, Dallas, Texas, USA) in paraffin-embedded samples of 30 cases of leukoplakia of all degrees of dysplasia and 21 cases of oral squamous cell carcinomas (OSCC) of all degrees of differentiation compared to the histologically normal oral epithelium. The samples were retrieved from 2009-2019 from the archives of the Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece. The samples were evaluated through a three-tier scale (positive cells Ι: 6-35%, ΙΙ: 36-70%, ΙΙΙ: 71-100%). Statistical analysis was performed through SPSS Pearson Chi-square, and the significance level was set at 0.05 (p=0.05). Results: The staining of ALDH1&2 was observed mildly in the cell membrane of cells in the stratum spinosum of the normal epithelium and the cell membrane of cells in the stratum basale of the normal epithelium, characteristically at the interface point with the basal membrane. ALDH1&2 were expressed significantly more in the OSCC than in the leukoplakia (p-value=0.0001) and the normal epithelium (p-value=0.0001). Mainly, ALDH1&2 were expressed significantly more in the severely and moderately dysplastic oral leukoplakia compared to the mildly dysplastic and non-dysplastic leukoplakia (p-value=0.001). The characteristic expression of ALDH in potentially malignant oral and OSCC lesions suggests the presence of CSCs and their possible implication in the early stages of oral tumorigenesis, even at the stage of oral leukoplakia.
Identifiants
pubmed: 37489188
doi: 10.7759/cureus.40836
pmc: PMC10363262
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e40836Informations de copyright
Copyright © 2023, Zisis et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Oral Oncol. 2020 Aug;107:104799
pubmed: 32446214
Oral Oncol. 2014 Dec;50(12):1144-8
pubmed: 25264224
Mol Med Rep. 2012 Apr;5(4):1116-20
pubmed: 22307065
Front Oncol. 2017 Jun 02;7:112
pubmed: 28626726
Oral Oncol. 2006 Nov;42(10):987-93
pubmed: 16731030
Oral Oncol. 2009 Apr-May;45(4-5):317-23
pubmed: 18674954
Front Mol Biosci. 2021 May 14;8:659550
pubmed: 34055881
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Mar;79(3):321-9
pubmed: 7621010
Oncol Rep. 2018 Dec;40(6):3843-3851
pubmed: 30542719
J Oral Maxillofac Pathol. 2017 Sep-Dec;21(3):461
pubmed: 29391735
Pathol Int. 2012 Dec;62(12):792-801
pubmed: 23252868
Med Oral Patol Oral Cir Bucal. 2013 Jan 01;18(1):e19-26
pubmed: 23085711
J Appl Oral Sci. 2013 Sep-Oct;21(5):460-7
pubmed: 24212993
Int J Cancer. 2013 Feb 15;132(4):868-74
pubmed: 22782852
J Oral Pathol Med. 2008 Mar;37(3):127-33
pubmed: 18251935
J Oral Pathol Med. 2013 Nov;42(10):755-60
pubmed: 23614644
World J Surg Oncol. 2013 Nov 22;11:298
pubmed: 24266898
Int J Oncol. 2014 Feb;44(2):435-42
pubmed: 24285422
Med Oral Patol Oral Cir Bucal. 2014 Jul 01;19(4):e386-90
pubmed: 24905952
Clin Oral Investig. 2014 Jan;18(1):199-210
pubmed: 23430339
Pathol Res Pract. 2016 Sep;212(9):791-9
pubmed: 27461829
BMC Cancer. 2015 Jul 07;15:502
pubmed: 26148881
Ann Hum Genet. 2009 May;73(Pt 3):335-45
pubmed: 19456322
Oral Oncol. 2017 Dec;75:140-147
pubmed: 29224811
J Oral Pathol. 1985 Oct;14(9):698-708
pubmed: 3932623
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):19-27
pubmed: 31110412
Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):537-542
pubmed: 29189260
Oncotarget. 2016 Mar 8;7(10):11018-32
pubmed: 26783961